© 2020 MJH Life Sciences and Endocrinology Network. All rights reserved.
© 2020 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
November 29, 2020
An analysis of data from the Women's Health Initiative suggests spending more than 6.5 hours engaged in sedentary behaviors each day was linked to a 42% increase in risk of heart failure in older women.
November 23, 2020
An analysis of cardiovascular outcomes from FIDELIO-DKD suggest finerenone use was associated with a 14% reduction in negative cardiovascular outcomes.
November 21, 2020
In a recent column Gregory Weiss, MD, uses studies from AHA Scientific Sessions 2020 to compare the cost-effectiveness of antihyperglycemic agents for reducing cardiovascular events.
November 20, 2020
An analysis of CDC data presented at AHA Scientific Sessions 2020 suggests rates of high blood pressure complications among pregnant women nearly doubled during a period lasting from 2008-2017.
November 19, 2020
An analysis from AHA 2020 suggests an HbA1c screening protocol doubled the proportion of patients with known dysglycemia when treating patients with ST-elevation myocardial infarction.
November 18, 2020
A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.
George Bakris, MD, discusses a study he took part in from AHA 2020 examining the number of diabetic patients meeting the American Diabetes Association's criteria for prescribing an SGLT2 inhibitor.
November 17, 2020
Data from a pair of phase 3 trials detail the effects of sotagliflozin in patients with type 2 diabetes and other comorbidities, such as worsening heart failure and chronic kidney disease.
November 16, 2020
Pooled analysis of SUSTAIN 6 and PIONEER 6 trials indicates the impact of semaglutide impact on MACE was present regardless of baseline triglyceride levels among diabetic patients.
Professor John McMurray explains why he is not as displeased as some colleagues are with the uptake of SGLT2 inhibitor prescribing rates for patients with heart failure or chronic kidney disease.